Sfoglia per AUTORE
MORO C
Collezione AO Cuneo

  

Items : 2

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer. in Cells / Cells. 2022 Oct 10;11(19):3176. doi: 10.3390/cells11193176.

2022
AO Cuneo
AOU Novara

De Cecco L; Licitra L; Bossi P; Ferraù F; Rinaldi G; Vaccher E; Moretti G; Denaro N; Caponigro F; Rocca MC; Secondino S; Moro C; Sponghini A; Caldara A; Ferrari D; Vecchio S; Lenoci D; Pistore F; Miceli R; Canevari S; Cavalieri S; Carenzo A; Serafini MS;

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2017 Nov 1;28(11):2820-2826. doi: 10.1093/annonc/mdx439.

2017
AOU Città della Salute di Torino
AO Cuneo
AOU Novara

Licitra L; Hollander L; Tettamanzi F; Ferrau F; Nolè F; Lo Vullo S; Rinaldi G; Caldara A; Sponghini A; Vaccher E; Moro C; Airoldi M; Caponigro F; Moretti G; Denaro N; Vecchio S; Ferrari D; Locati LD; Miceli R; Bossi P;